NeutraKine® IL-10 Monoclonal antibody
NeutraKine® IL-10 Monoclonal Antibody for IHC, Neutralization, ELISA
Host / Isotype
Mouse / IgG1
Human and More (1)
Neutralization, IHC, ELISA
Cat no : 69018-1-Ig
Validation Data Gallery
69018-1-Ig targets NeutraKine® IL-10 in Neutralization, IHC, ELISA applications and shows reactivity with Human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||human Humankine IL-10 protein HZ-1145|
|Full Name||interleukin 10|
|Gene ID (NCBI)||3586|
|Purification Method||Protein G purification|
|Storage Buffer||Sterile PBS.|
|Reconstitution||This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.|
|Stability and Storage||Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.|
Interleukin (IL)-10 is an anti-inflammatory cytokine, produced by T helper (Th) cells, macrophages, monocytes, and B cells, that plays a crucial role in preventing inflammatory and autoimmune pathologies. It downregulates the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. IL-10 can block NF-κB activity, and is involved in the regulation of the JAK-STAT signaling pathway. IL-10, along with its receptors, describes an important role in pathogenesis of various diseases, including infectious, inflammatory, autoimmune diseases. IL-10 mutations are associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis.
This antibody can be used to neutralize the bioactivity of IL-10.
|Product Specific Protocols|
|IHC protocol for NeutraKine® IL-10 antibody 69018-1-Ig||Download protocol|
|Click here to view our Standard Protocols|
Front Cell Dev Biol
Melatonin Promotes the Therapeutic Effect of Mesenchymal Stem Cells on Type 2 Diabetes Mellitus by Regulating TGF-β Pathway.
Int J Biol Sci
NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.